JAZZ PHARMACEUTICALS PLC

Jazz Pharmaceuticals shares rise 1.26% to $214.65 as investors weigh upcoming Q2 FY27 results, market cap $13.8 bn, and its portfolio in narcolepsy, oncology and pain.

Jazz Pharmaceuticals (JAZZ) trades near its 200‑day SMA with upside potential. 12% drop reflects sector softness, yet 52‑week low offers room for growth if pipeline catalysts hit.